Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 132 - You Need To See This

Biological weapons threat evolving, experts say

WASHINGTON — The threat from biological weapons use by nations or terrorists is entering an era of potentially heightened risk, but the dimensions of the danger are not yet clear, a panel of experts said Friday.

Tribune News Service

Family Dollar recalls Colgate products that were improperly stored

Family Dollar says it is not aware of any complaints from customers nor any reports of illnesses related to the recall.

WEKU

Jury says Sterigenics should pay $363 million to Illinois woman for exposing her to cancer-causing ethylene oxide

Sterigenics, its parent company and a corporate predecessor should pay $363 million in damages for exposing a Willowbrook, Illinois, woman and thousands of others to cancer-causing ethylene oxide pollution, a Cook County jury decided Monday.

Chicago Tribune

From analysis to the latest developments in health,
read the most diverse news in one place.

The tide turns against superbugs

Humans were losing the war against antibiotic-resistant superbugs. Is that about to change?

Salon

Check Out What Whales Are Doing With BNTX

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Fauci warns strengthening anti-vax movement may lead to ‘tragic and avoidable’ outbreaks among children

According to WHO data, the rates of typical childhood vaccinations have only fallen a point between 2021 and 2020

The Independent UK

Doctors rush to use Supreme Court ruling to escape opioid charges

Dr. Nelson Onaro conceded last summer that he’d written illegal prescriptions, although he said he was thinking only of his patients. From a tiny clinic in Oklahoma, he doled out hundreds of opioid pills and dozens of fentanyl patches with no legitimate medical purpose.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Should You Buy This Biotech Stock Near Its 52-Week Low?

Recently listed biotech stock Comera Life Sciences is trading near its 52-week low. The stock is down more than 75% year-to-date. Although the $15 million purchase agreement with Arena Business Solutions is expected to help it invest in its product pipeline and formulation platform SQore, will it be wise to…

StockNews.com

Brazil approves Pfizer vaccine for children as young as six months

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Reuters

FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

Benzinga

1 Stock You'll Wish You Bought Sooner

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

StockNews.com

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

StockNews.com

America's fentanyl problem a growing threat for teens

America's epidemic of drug overdoses tied to fentanyl is a growing threat for teens, particularly as the pills are increasingly disguised, officials warn.

Axios

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

StockNews.com

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

The Independent UK

US warns monkeypox could mutate to resist antiviral drug

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox

Irish Mirror

Pharma services company's shares go up by 12% after it confirms insider dealing probe

Dublin-listed Open Orphan confirmed it is helping gardai in respect of the investigation

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

This 1 Stock Pays You Just for Owning It

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

The Hindu

Payment of ₹200 crore to drug companies for supply of Remdesivir in Karnataka stuck due to breach of tender condition

More than a year after the drug was supplied, payments to major pharma companies are stalled due to this violation.

Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

StockNews.com

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

Tribune News Service

New ALS drug funded by Ice Bucket Challenge already in use in South Florida trials

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

Salon

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Tribune News Service

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

1 … 131 132 133 134

People

Joe Biden

68,619 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

349 stories

PFE

346 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.